Journal article
Inhibitor development in haemophilia according to concentrate
Abstract
Inhibitor development represents the most serious side effect of haemophilia treatment. Any difference in risk of inhibitor formation depending on the product used might be of clinical relevance. It was this study's objective to assess inhibitor development according to clotting factor concentrate in severe haemophilia A and B. The European Haemophilia Safety Surveillance (EUHASS) was set up as a study monitoring adverse events overall and …
Authors
Fischer K; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Iorio A; Gilman E; Makris M
Journal
Thrombosis and Haemostasis, Vol. 113, No. 05, pp. 968–975
Publisher
Thieme
Publication Date
September 2015
DOI
10.1160/th14-10-0826
ISSN
0340-6245